Q2 2023 Highlights
- Revenues of $24.5 million,
versus $32.1 million in Q2
2022
- Net income of $0.4 million,
versus $3.4 million in prior
year
- Cash available for operating activities totaled $14.3 million at quarter end, including a cash
balance of
$3.0 million and another $11.3 million under Imaflex's $12.0 million revolving line of credit
- New extruder and metalizer at our Victoriaville facility are now fully
operational
MONTRÉAL, Aug. 29,
2023 /CNW/ - Imaflex Inc. ("Imaflex" or the
"Corporation") (TSXV: IFX) reports consolidated financial results
for the second quarter (Q2) ended June 30,
2023 and provides a business update. All amounts are in
Canadian dollars.
"We successfully navigated another challenging quarter in a
demanding operating environment," commented Mr. Joe Abbandonato, President and Chief Executive
Officer of Imaflex. "Sales volumes strengthened versus the first
quarter of 2023 and we remain cautiously optimistic they will
continue to build over the remainder of the year. The new extruder
and metalizer at our Victoriaville facility are now fully
operational and we are working hard to boost equipment utilization
levels across the business, while also heightening
profitability."
Consolidated Financial Highlights (unaudited)
|
Three months ended June
30,
|
Six months ended June
30,
|
CDN $ thousands,
except per share amounts
(or otherwise
indicated)
|
2023
|
2022
|
% Change
|
2023
|
2022
|
% Change
|
Revenues
|
24,494
|
32,123
|
(23.7) %
|
47,730
|
63,187
|
(24.5) %
|
Gross Profit
|
3,428
|
5,598
|
(38.8) %
|
6,608
|
10,368
|
(36.3) %
|
Selling & admin.
expenses
|
2,412
|
2,105
|
14.6 %
|
4,355
|
4,032
|
8.0 %
|
Other (gains)
losses
|
395
|
(644)
|
161.3 %
|
391
|
(351)
|
211.4 %
|
Net income
|
438
|
3,419
|
(87.2) %
|
1,361
|
5,502
|
(75.3) %
|
Basic EPS
|
0.01
|
0.07
|
(85.7) %
|
0.03
|
0.11
|
(72.7) %
|
Diluted EPS
|
0.01
|
0.07
|
(85.7) %
|
0.03
|
0.11
|
(72.7) %
|
Gross margin
|
14.0 %
|
17.4 %
|
(3.4)
pp
|
13.8 %
|
16.4 %
|
(2.6)
pp
|
Selling & admin.
expenses as % of revenues
|
9.8 %
|
6.6 %
|
3.2 pp
|
9.1 %
|
6.4 %
|
2.7 pp
|
EBITDA1 (Excluding FX)
|
2,115
|
4,479
|
(52.8) %
|
4,286
|
8,307
|
(48.4) %
|
EBITDA
|
1,689
|
5,123
|
(67.0) %
|
3,895
|
8,658
|
(55.0) %
|
EBITDA
margin
|
6.9 %
|
15.9 %
|
(9.0)
pp
|
8.2 %
|
13.7 %
|
(5.5)
pp
|
____________________________________________
|
1 See
header titled "Caution Regarding non-IFRS Financial Measures" which
follows.
EBITDA: Earnings Before Interest, Taxes, Depreciation, and
Amortization
|
Financial Review: Quarter Ended June
30
Revenues
Revenues were $24.4 million for
the second quarter of 2023, down 23.7% from $32.1 million in 2022. The decrease was driven by
lower volumes and reduced selling prices resulting from
the passthrough of a drop in resin costs and a competitive
pricing environment. This was partially offset by favourable
year-over-year movements in foreign exchange. As Imaflex has
no long-term contracts, it can adjust product pricing in accordance
with resin input costs.
Revenues came in at $47.7 million
for the first six months of 2023, down 24.5% versus the
corresponding prior-year period. The decrease was driven by the
same factors outlined for the quarter.
Gross Profit
Gross profit came in at $3.4
million (14.0% of sales) in the current quarter, versus
$5.6 million (17.4% of sales) in the
prior year. For 2023 year-to-date, the gross profit came in at
$6.6 million (13.8% of sales), versus
$10.4 million (16.4% of sales) in
2022.
For both the current quarter and first half of 2023, the impact
of the decreased gross profit on the gross margin was reduced by
the lower 2023 sales base and favourable year-over-year movements
in foreign exchange.
Operating Expenses
Selling and Administrative expenses were $2.4 million (9.8% of sales) for the quarter, up
14.6% from $2.1 million (6.6% of
sales) in 2022. For the year-to-date, Selling and Administrative
expenses came in at $4.4 million
(9.1% of sales) up from $4.0 million
(6.4% of sales) in 2022. The year-over-year expense increases for
the quarter and first six months of 2023 were largely due to new
employee hires, salary increases to remain competitive in the
market and higher non-cash stock-based compensation expenses.
Selling expenses as a percentage of sales were also impacted by the
lower sales base in 2023.
Imaflex recorded other losses of $0.4
million for the current quarter, versus a gain of
$0.6 million in the prior year
quarter, resulting in a $1.0 million
unfavourable year-over-year variance. The current quarter
includes $31 thousand of interest income (nil in 2022), along
with a $0.4 million foreign exchange
(FX) loss. For 2023 year-to-date, the Company had losses of
$0.4 million versus gains of
$0.3 million in the corresponding
prior-year period, resulting in a year-over-year unfavourable
variance of $0.7 million. The first
six months of 2023 include $86
thousand of interest income (nil in 2022) and a $0.5 million foreign exchange loss.
A majority of the Corporation's foreign exchange gains and
losses are non-cash impacting and largely relate to intercompany
balances for which Imaflex can control the time of
settlement.
Net Income and EBITDA
Net income was $0.4 million for
the current quarter, down from $3.4
million in the second quarter of 2022. The year-over-year
decrease was driven by the lower 2023 gross profit, along with the
aforementioned foreign exchange losses, and higher selling and
administrative expenses. For the year-to-date, net income stood at
$1.4 million, down from $5.5 million in the corresponding period of 2022.
The decrease from 2022 was due to the same factors outlined for the
quarter.
EBITDA came in at $1.7 million
(6.9% of sales) for the current quarter, down from $5.1 million (15.9% of sales) in 2022. On a
constant currency basis, EBITDA came in at $2.1 million (8.6% of sales) for the current
quarter, down from $4.5 million
(13.9% of sales) in 2022. For the first six months of 2023, EBITDA
stood at $3.9 million (8.2% of sales)
versus $8.7 million (13.7% of sales)
in the corresponding prior-year period. On a constant currency
basis EBITDA came in at $4.3 million
(9.0% of sales) for 2023 year-to-date, compared with $8.3 million (13.1% of sales) in 2022.
Liquidity and Capital Resources
Net cash flows generated by operating activities, before
movements in working capital and taxes paid, stood at $2.3 million for the current quarter, down from
$4.6 million in 2022. The
$2.2 million decrease was largely due
to the lower year-over-year profit, partially offset by movements
in foreign exchange. Including movements in working capital and
taxes paid, the Company recorded net cash outflows by operating
activities of $1.8 million for the
current quarter. This compares to cash inflows of $3.7 million in the corresponding prior-year
period. The decrease versus 2022 is mainly due to the lower profit,
along with movements in inventories, prepaid expenses, and trade
receivables.
For the year-to-date, cash flows generated by operating
activities, including movements in working capital and taxes paid,
stood at $1.7 million, versus
$7.0 million in the corresponding
prior-year period. The decrease versus 2022 is mainly due to the
lower profit in 2023, along with movements in inventories and
prepaid expenses, partially offset by movements in trade and other
payables.
As at June 30, 2023, cash
available for operating activities totaled $14.3 million, including a cash balance of
$3.0 million and another $11.3 million under Imaflex's $12.0 million revolving line of credit. This
strong position was achieved despite $2.8
million of payments in the quarter, largely towards the
major equipment purchases announced in Q2 2022. These investments
further enhance the Company's production capacity and capabilities
to heighten sales and profitability.
Outlook
"Economic headwinds, customer destocking and a competitive
pricing environment impacted results for the first half of 2023,"
said Mr. Abbandonato. "While these challenges persist, we
anticipate their impact to ease as the year unfolds. We are
optimistic market softness will gradually stabilize, resulting in
stronger performance for the latter half of 2023. Our financial
position remains strong, and we are working hard to fill unused
capacity and find new opportunities. We remain steadfast in our
approach and believe we are well positioned to navigate these
dynamic markets and build for a promising future."
Caution Regarding Non-IFRS Financial Measures
The Company's management uses non-IFRS measures in this press
release, namely EBITDA (Earnings Before Interest, Taxes,
Depreciation, and Amortization), EBITDA excluding foreign
exchange.
While EBITDA is not a standard International Financial Reporting
Standards (IFRS) measure, management, analysts, investors and
others use it as an indicator of the Company's financial and
operating management and performance. EBITDA should not be
construed as an alternative to net income determined in accordance
with IFRS as an indicator of the Company's performance. The
Company's method of calculating EBITDA may be different from those
used by other companies and accordingly they should not be
considered in isolation.
About Imaflex Inc.
Founded in 1994, Imaflex is focused on the development and
manufacturing of innovative solutions for the flexible packaging
space. Concurrently, the Corporation develops and manufactures
films for the agriculture industry. The Corporation's products
consist primarily of polyethylene (plastic) film and bags,
including metalized plastic film, for the industrial,
agricultural and consumer markets. Headquartered in Montreal, Quebec, Imaflex has manufacturing
facilities in Canada and
the United States. The
Corporation's common stock is listed on the TSX Venture
Exchange under the ticker symbol IFX. Additional information is
available at www.imaflex.com.
Cautionary Statement on Forward Looking Information
Certain information included in this press release
constitutes "forward-looking" statements within the meaning of
Canadian securities laws. Forward-looking statements are
necessarily based upon a number of estimates and assumptions that,
while considered reasonable by the management of the Corporation,
are inherently subject to significant business, economic and
competitive uncertainties, risks and contingencies. The Corporation
cautions the reader that such forward-looking statements involve
known and unknown risks, uncertainties and other factors that may
cause the actual financial results, performance or achievements
of Imaflex to be materially different from the Corporation's
estimated future results, performance or achievements expressed or
implied by those forward-looking statements and that the
forward-looking statements are not guarantees of future
performance. These statements are also based on certain factors and
assumptions. For more details on these estimates, risks,
assumptions and factors, see the Corporation's most recent
Management Discussion and Analysis filed on SEDAR
at www.sedar.com and on the investor section of the
Corporation's website at www.imaflex.com. The Corporation disclaims
any obligation to update or revise any forward-looking statements,
whether as a result of new information, events or otherwise, except
as expressly required by law. Readers are cautioned not to put
undue reliance on these forward-looking statements.
Neither the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE Imaflex Inc.